WHO ICTRP trial
A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF¨¢…
NL-OMON28713 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON28713 |
|---|---|
| Public title | A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF¨¢ Chimeric Monoclonal Antibody (Infliximab, Remicade®) in Combination with Methotrexate in Patients with Very Early Inflammatory Arthritis. |
| Scientific title | A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF¨¢ Chimeric Monoclonal Antibody (Infliximab, Remicade®) in Combination with Methotrexate in Patients with Very Early Inflammatory Arthritis. |
| Primary sponsor | Josef S. Smolen MD Department of Rheumatology Medical University of Vienna Waehringer Guertel 18-20 A-1090 Vienna, Austria +43-1-40400-4300 [email protected] |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | Very early inflammatory arthritis. |
| Interventions | 200 subjects (80 per DMARD treatment arm and 40 in the supportive treatment arm) will be randomly assigned, stratified by glucocorticoid use to one of the following treatment groups: Group I: To receive symptomatic therapy as well as oral… |
| Registration date | Oct 1, 2007 |
| Target size | 200 |
| Secondary IDs | NL1045;NTR1078; : DINORA4;ISRCTN21272423 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: